An assessment by the Statin diabetes safety task force: 2014 update

Journal of Clinical Lipidology

Volumn 8, Issue 3 SUPPL, 2014, Pages

  Maki, Kevin C ^a   Ridker, Paul M ^b   Brown, W Virgil ^c   Grundy, Scott M ^d   Sattar, Naveed ^e  

^a DEPAUL UNIVERSITY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Coronary heart disease; Lipid; National Lipid Association; Statin; Type 2 diabetes mellitus

Indexed keywords

ATORVASTATIN; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ARTICLE; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG LABELING; DRUG SAFETY; DRUG USE; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HAZARD RATIO; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SCREENING; SECONDARY PREVENTION; ANALYSIS; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; PRACTICE GUIDELINE; RISK;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ODDS RATIO; RISK FACTORS;

EID: 84899805037     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2014.02.012     Document Type: Article

References (56)

1. N.J. Stone, J. Robinson, and A.H. Lichtenstein et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [e-pub ahead of print] J Am Coll Cardiol 2013 10.1016/j.jacc.2013.11.002 Accessed March 14, 2014
2. G.H. Guyatt, A.D. Oxman, and G.E. Vist et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations BMJ 336 2008 924 926
3. P.A. James, S. Oparil, and B.L. Carter et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) JAMA 311 2014 507 520
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
5. S.M. Grundy, J.I. Cleeman, C.N. Merz Coordinating Committee of the National Cholesterol Education Program Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines J Am Coll Cardiol 44 2004 720 732
6. Expert Dyslipidemia Panel S.M. Grundy An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia J Clin Lipidol 7 2013 561 565
7. Cholesterol Treatment Trialists (CTT) Collaborators C. Baigent, L. Blackwell, and J. Emberson et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
8. Cholesterol Treatment Trialists (CTT) Collaborators B. Mihaylova, J. Emberson, and L. Blackwell et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials Lancet 380 2012 581 590
9. F. Taylor, M.D. Huffman, and A.F. Macedo et al. Statins for the primary prevention of cardiovascular disease Cochrane Database Syst Rev 1 2013 CD004816
10. P.M. Ridker, E. Danielson, and F.A. Fonseca et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
11. Astra Zeneca. Clinical briefing document - Endocrine and Metabolic Drugs Advisory Committee meeting for rosuvastatin (Crestor). Available at: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/ drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm193831.pdf. Accessed November 5, 2013.
12. S.N. Rajpathak, D.J. Kumbhani, J. Crandall, N. Barzilai, M. Alderman, and P.M. Ridker Statin therapy and risk of developing type 2 diabetes: a meta-analysis Diabetes Care 32 2009 1924 1929
13. N. Sattar, D. Preiss, and H.M. Murray et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 742
14. D. Preiss, S.R. Seshasai, and P. Welsh et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis JAMA 305 2011 2556 2564
15. D.D. Waters, J.E. Ho, and D.A. DeMicco et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials J Am Coll Cardiol 57 2011 1535 1545
16. Food and Drug Administration. FDA drug safety communication: important safety label changes to cholesterol lowering statin drugs. Available at: http://www.fda.gov/drugs/drugsafety/ucm293101.htm. Accessed November 6, 2013.
17. The National Lipid Association. FDA changes label on statin drugs. Available at: https://www.lipid.org/communications/news/other/fda-changes
18. D.D. Waters, J.E. Ho, and S.M. Boekholdt et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes J Am Coll Cardiol 61 2013 148 152
19. C. Baigent, A. Keech, P.M. Kearney Cholesterol Treatment Trialists Committee Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
20. P.M. Ridker, A. Pradhan, J.G. MacFadyen, P. Libby, and R.J. Glynn Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial Lancet 380 2012 565 571
21. H.M. Colhoun, D.J. Betteridge, P.N. Durrington CARDS investigators Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
22. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
23. R. Collins, J. Armitage, S. Parish, P. Sleigh, R. Peto Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial Lancet 361 2003 2005 2016
24. R.R. Holman, S. Paul, A. Farmer, L. Tucker, I.M. Stratton, H.A. Neil Atorvastatin in Factorial with Omega 3 EE90 Risk Reduction in Diabetes Study Group Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial Diabetologia 52 2009 50 59
25. Y. Zhou, Y. Yuan, and R.R. Cai et al. Statin therapy on glycaemic control in type 2 diabetes: a meta-analysis Expert Opin Pharmacother 14 2013 1575 1584
26. D.C. Goff Jr., D.M. Lloyd-Jones, and G. Bennet et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [e-pub ahead of print] J Am Coll Cardiol 2013 10.1016/j.jacc.2013.11. 005 Accessed March 14, 2014
27. W.C. Knowler, E. Barrett-Connor, S.E. Fowler Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 2002 393 403
28. A.G. Tabak, C. Herder, W. Rathmann, E.J. Brunner, and M. Kivimaki Prediabetes: a high-risk state for diabetes development Lancet 379 2012 2279 2290
29. American Diabetes Association Standards of medical care in diabetes-2014 Diabetes Care 37 Suppl 1 2014 S14 S80
30. R.A. Defronzo Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus Diabetes 58 2009 773 795
31. J.E. Gerich Measurements of renal glucose release Diabetes 50 2001 905
32. W.L. Baker, R. Talati, C.M. White, and C.I. Coleman Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis Diabetes Res Clin Pract 87 2010 98 107
33. C. Lamendola, F. Abbasi, and J.W. Chu et al. Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia Am J Cardiol 95 2005 189 193
34. A. Abbas, J. Milles, and S. Ramachandran Rosuvastatin and atorvastatin: comparative effects on glucose metabolism in non-diabetic patients with dyslipidaemia Clin Med Insights Endocrinol Diabetes 5 2012 13 30
35. H. Sato, G. Carvalho, and T. Sato et al. Statin intake is associated with decreased insulin sensitivity during cardiac surgery Diabetes Care 35 2012 2095 2099
36. R. Muniyappa, S. Lee, H. Chen, and M.J. Quon Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage Am J Physiol Endocrinol Metab 294 2008 E15 E26
37. S.P. Choukem, and J.F. Gautier How to measure hepatic insulin resistance? Diabetes Metab 34 2008 664 673
38. U.K. Sampson, M.F. Linton, and S. Fazio Are statins diabetogenic? Curr Opin Cardiol 26 2011 342 347
39. M. Banach, M. Malodobra-Mazur, A. Gluba, N. Katsiki, J. Rysz, and A. Dobrzyn Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance Curr Pharm Des 19 2013 4904 4912
40. M.R. Goldstein, and L. Mascitelli Do statins cause diabetes? Curr Diab Rep 13 2013 381 390
41. K.A. Jandeleit-Dahm, C. Tikellis, C.M. Reid, C.I. Johnston, and M.E. Cooper Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes J Hypertens 23 2005 463 473
42. W.J. Elliott, and P.M. Meyer Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis Lancet 369 2007 201 207
43. H. Chatterton, T. Younger, A. Fischer, K. Khunti Programme Development Group Risk identification and interventions to prevent type 2 diabetes in adults at high risk: summary of NICE guidance BMJ 345 2012 e4624
44. InterAct Consortium The link between family history and risk of type 2 diabetes is not explained by anthropometric, lifestyle or genetic risk factors: the EPIC-InterAct study Diabetologia 56 2013 60 69
45. M. Heller The DASH Diet Weight Loss Solution: 2 Weeks to Drop Pounds, Boost Metabolism, and Get Healthy (A DASH Diet Book) 2012 Grand Central Life & Style, Hachette Book Group New York, NY
46. D.B. Sacks, M. Arnold, G.L. Bakris National Academy of Clinical Biochemistry, Evidence-Based Laboratory Medicine Committee of the American Association for Clinical Chemistry Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus Diabetes Care 34 2011 e61 e99
47. N. Ewald, C. Kaufmann, A. Raspe, H.U. Kloer, R.G. Bretzel, and P.D. Hardt Prevalence of diabetes mellitus secondary to pancreatic diseases (type 3c) Diabetes Metab Res Rev 28 2012 338 342
48. E.L. Lim, K.G. Hollingsworth, B.S. Aribisala, M.J. Chen, J.C. Mathers, and R. Taylor Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol Diabetologia 54 2011 2506 2514
49. R. Taylor Banting Memorial lecture 2012: reversing the twin cycles of type 2 diabetes Diabet Med 30 2013 267 275
50. R.A. DeFronzo, and M. Abdul-Ghani Type 2 diabetes can be prevented with early pharmacological intervention Diabetes Care 34 Suppl 2 2011 S202 S209
51. R.R. Wing, W. Lang, and T.A. Wadden et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes Diabetes Care 34 2011 1481 1486
52. M.A. Espeland, W.J. Rejeski, D.S. West Action for Health in Diabetes Research Group Intensive weight loss intervention in older individuals: results from the Action for Health in Diabetes Type 2 diabetes mellitus trial J Am Geriatr Soc 61 2013 912 922
53. Cholesterol Treatment Trialists (CCT) Collaborative P.M. Kearney, L. Blackwell, and R. Collins et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371 2008 117 125
54. F.R. Danesh, and Y.S. Kanwar Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy FASEB J 18 2004 805 815
55. S. Ludwig, and G.X. Shen Statins for diabetic cardiovascular complications Curr Vasc Pharmacol 4 2006 245 251
56. K. Pyorala, T.R. Pedersen, J. Kjekshus, O. Faergeman, A.G. Olsson, and G. Thorgeirsson Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care 20 1997 614 620